S9 Ep2: FDA Approval Insights: Epcoritamab in Relapsed/Refractory DLBCL
Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.